Generic and therapeutic substitutions in the UK: are they a good thing?
about
What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugsBehaviour change interventions to promote prescribing of generic drugs: a rapid evidence synthesis and systematic reviewThe experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine useSwitching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy.Potential Clinical and Economic Impact of Switching Branded Medications to Generics.Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.The economics of medicines optimization: policy developments, remaining challenges and research priorities.Editors' pick 2010.A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.Policies to enhance prescribing efficiency in europe: findings and future implications.Drug selection in French university hospitals: analysis of formularies for nine competitive pharmacological classes.Community pharmacists' attitudes toward the quality and price of locally manufactured generic medicines in Kabul, Afghanistan.Generic drugs: Review and experiences from South India.Implementing a statin switching programme in primary care: patients' views and experiences.Ethical issues raised by the introduction of payment for performance in FranceImproving viable low cost generic medication prescription rate in primary care pediatric practice.Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines.Is there a need for a formulary of clinically interchangeable medicines to guide generic substitution in Saudi Arabia?Effects of hospital generic drug substitution on diabetes therapy.Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspective.Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.Generic medicines: issues and relevance for global health.Nonbioequivalent prescription drug interchangeability, concerns on patient safety and drug market dynamics in Brazil.Has cost inhibited the uptake of more potent statins in England?Bias within economic evaluations - the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug.Issues potentially affecting quality of life arising from long-term medicines use: a qualitative study.Tackling disinvestment in health care services. The views of resource allocators in the English NHS.Generic medicine substitution: a cross-sectional survey of the perception of pharmacists in North-Central, Nigeria.Projecting expenditure on medicines in the UK NHS.Safety and efficiency of a new generic package labelling: a before and after study in a simulated setting.The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians.Medication dispensing errors in Palestinian community pharmacy practice: a formal consensus using the Delphi technique.Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study.Substitutes of Prescription Medicines - A Review of Concerns Relevant to Doctors and Patients.The complex legal and ethical issues related to generic medications. Viral hepatitis: a case studyFrom NCE to NICE: the role of pharmacoeconomics.The association between automatic generic substitution and treatment persistence with oral bisphosphonates.Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.Generic substitution: a need for clarification.
P2860
Q26801726-7B8E098E-3176-4288-8E10-605640BEBF65Q26866161-FC600651-E086-46CA-AA2D-1ECB52D2362EQ27007695-01496FA0-2081-4D71-A206-42CF713435E1Q30978981-C4DF00A7-ECF1-4A22-BE86-C989D8552D20Q33637817-C184391D-94E8-44E2-A773-B98D40CF1923Q33816182-96C14489-188D-44EA-B2DE-6731EC32EA7FQ34132415-A9B47076-75E5-4723-A974-248D320F1CCAQ34476042-FC906B2B-E1A4-4074-9424-542DE7668FAFQ34536861-6538F4FB-3178-4153-AA9A-A879F56D357DQ35155250-FD11F1C8-6C41-448C-A2C9-CEE6D55C932EQ35624615-BF0E8878-A9A9-4B24-A90F-88AF069B0734Q35741403-F629F67F-8A25-4058-8901-3E809055E7F4Q35948976-C94EBFB8-E6DB-4152-A155-79B0E9F644F1Q36087995-735D628A-F035-4129-ACDE-BE67A117E49AQ36105652-7FC3C70C-99B1-4C6D-94D4-9D90491D8C55Q36409306-2F2AD3EC-91AB-432B-81E4-D962100AD13FQ36924615-328DABF1-7731-447E-AA60-C76EFE61B0B7Q37134436-645C4197-1969-477F-8099-AABF2733281EQ37554240-05C67207-E5C8-45C4-8F57-3A6F93F78179Q37707392-C24D96B9-0B36-440C-B0AC-CB8623840E60Q38131544-E35D5812-1EB0-4ACF-B4C7-2D64C2643581Q38517704-2DA12BB5-0A1C-4045-86EC-96181F0E00E8Q38592725-5D0C1F00-64BB-488A-9968-CD26234AF5D7Q38632178-8E7145FA-41AC-4E00-A33B-56127E34CCDAQ38726224-CA0E88A0-C058-42CC-8C78-258ADD8B353BQ38949634-CDD8B482-BF98-4473-92B4-2AEF4A727F71Q39221443-8469FA28-79EF-4FFD-A931-E2A54770A0EFQ39273040-0C57E130-9AFE-49FF-86AA-3AA236FE38EDQ39317365-8A273844-1AAF-4D8B-A9B5-001167320917Q39350064-37CAD404-7423-4EBC-AF53-CFFAB14D4942Q40232306-89DA92EF-93D9-401C-B971-E306111929B7Q40322708-0B693F06-62D1-4086-9654-8DB9A3621DE3Q40672584-FA991AF0-227F-43EF-953B-52415826FAF8Q41654265-84E9840B-5E77-4087-B244-F1D9521E4B3EQ42029035-7536EC86-4CB4-4E70-9994-E84F959B4C54Q42365538-E9F90EF3-EE75-43B8-BAF0-08085FB90B59Q42414047-17900100-87CE-4004-AD48-D12D7C5487F4Q42626603-21D04490-9C4C-4056-A337-CCDEC3A804DEQ42687717-ECD96A18-F066-44CF-9403-8687AC295F7BQ42737339-2D46AB02-EDEE-4B83-B8E8-1FC7FB5CC32F
P2860
Generic and therapeutic substitutions in the UK: are they a good thing?
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Generic and therapeutic substitutions in the UK: are they a good thing?
@ast
Generic and therapeutic substitutions in the UK: are they a good thing?
@en
Generic and therapeutic substitutions in the UK: are they a good thing?
@nl
type
label
Generic and therapeutic substitutions in the UK: are they a good thing?
@ast
Generic and therapeutic substitutions in the UK: are they a good thing?
@en
Generic and therapeutic substitutions in the UK: are they a good thing?
@nl
prefLabel
Generic and therapeutic substitutions in the UK: are they a good thing?
@ast
Generic and therapeutic substitutions in the UK: are they a good thing?
@en
Generic and therapeutic substitutions in the UK: are they a good thing?
@nl
P2860
P1476
Generic and therapeutic substitutions in the UK: are they a good thing?
@en
P2093
Martin G Duerden
P2860
P304
P356
10.1111/J.1365-2125.2010.03718.X
P407
P577
2010-09-01T00:00:00Z